Injectable LHRH agonist now available nationwide

April 8, 2005

The FDA has approved triptorelin pamoate for injectable suspension (Trelstar Depot, 3.75 mg, and Trelstar LA 11.25 mg). The sustained-release, 1- and 3-month intramuscular injectable formulations are now available nationwide for the palliative treatment of advanced prostate cancer when orchiectomy or estrogen administration are either not indicated or are unacceptable to the patient.

The FDA has approved triptorelin pamoate for injectable suspension (Trelstar Depot, 3.75 mg, and Trelstar LA 11.25 mg). The sustained-release, 1- and 3-month intramuscular injectable formulations are now available nationwide for the palliative treatment of advanced prostate cancer when orchiectomy or estrogen administration are either not indicated or are unacceptable to the patient.

Clinical studies showed more than 94% of about 600 patients receiving the injection maintained castrate testosterone levels from the second to ninth month. Studies also showed that PSA levels were reduced by 97% through the ninth month.